IOVANCE BIOTHERAPEUTICS, INC.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $99.3M | $71.4M | $86.8M | $67.5M | $60.0M | $49.3M | $73.7M | $58.6M |
| Cost of Revenue | $43.6M | $42.5M | $43.1M | $38.5M | $48.9M | $42.7M | $23.1M | $31.5M |
| Gross Profit | $55.7M | $28.9M | $43.7M | $29.0M | $11.1M | $6.6M | $50.6M | $27.0M |
| Gross Margin | 56.1% | 40.5% | 50.3% | 43.0% | 18.5% | 13.4% | 68.7% | 46.2% |
| Operating Expenses | ||||||||
| Research & Development | $58.9M | $62.5M | $71.2M | $75.2M | $77.9M | $76.0M | $67.3M | $67.0M |
| SG&A Expense | $39.3M | $38.9M | $36.4M | $34.6M | $37.6M | $43.8M | $42.0M | $39.3M |
| Operating Income | $-51.9M | $-81.0M | $-73.5M | $-94.9M | $-113.8M | $-121.2M | $-86.6M | $-89.1M |
| Operating Margin | -52.3% | -113.5% | -84.7% | -140.7% | -189.8% | -245.8% | -117.5% | -152.1% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-48.7M | $-79.7M | $-71.7M | $-93.7M | $-109.7M | $-118.0M | $-77.0M | $-85.1M |
| Income Tax Expense | $-1.4M | $-665.0K | $184.0K | $-2.4M | $2.0M | $-1.8M | $1.6M | $-1.5M |
| Net Income | $-47.3M | $-79.0M | $-71.9M | $-91.3M | $-111.7M | $-116.2M | $-78.6M | $-83.5M |
| Net Margin | -47.6% | -110.7% | -82.9% | -135.3% | -186.2% | -235.5% | -106.6% | -142.7% |
| EPS (Basic) | $-0.11 | $-0.19 | $-0.15 | $-0.25 | $-0.33 | $-0.36 | $-0.24 | $-0.28 |
| EPS (Diluted) | $-0.11 | $-0.19 | — | — | $-0.33 | $-0.36 | $-0.24 | $-0.28 |
| Shares Outstanding (Basic) | 450.2K | 418.5K | 357.3K | 364.0K | 334.5K | 322.9K | 289.9K | 303.3K |
| Shares Outstanding (Diluted) | 450.2K | 418.5K | 357.3K | 364.0K | 334.5K | 322.9K | 289.9K | 303.3K |
| Dividends Per Share | — | — | — | — | — | — | — | — |